Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical
company developing novel therapeutics and delivery methods for
breast cancer and other breast conditions has contracted with a
leading European hospital to conduct a Phase 2 study of its
proprietary topical Endoxifen for the treatment of women with
mammographic breast density, or MBD. Studies by others have shown
that a reduction in MBD reduces the risk of developing breast
cancer. The Phase 2 study will be conducted at Stockholm South
General Hospital in Sweden and will be led by principal
investigator Dr. Per Hall, MD, Ph.D., Head of the Department of
Medical Epidemiology and Biostatistics at Karolinska Institutet.
“Dr. Hall is widely regarded as a leading researcher in the
field of breast cancer and prevention. He is heading the
unique KARMA (Karolinska Mammography Project for Risk Prediction of
Breast Cancer) Cohort, including over 70,000 women, which is
regarded as the best characterized breast cancer cohort in the
world and serves as a resource for studies about breast cancer risk
assessment and prevention, and the Karisma Intervention Study,
which is studying the change in MBD in women taking various doses
of oral tamoxifen. We are honored to be working with Dr. Hall and
his colleagues on our Phase 2 study of MBD as their unique
experience and qualifications are simply unmatched anywhere in the
world,” said Dr. Steven C. Quay, CEO and President of Atossa
Genetics.
Atossa plans to apply for approval from the Institutional Review
Board and Swedish regulatory authority (Medical Products Agency)
within the next 30 days. The placebo-controlled, double-blinded
study is expected to enroll up to 480 subjects. The primary
endpoint is MBD reduction, which will be measured after six and
twelve months of dosing, as well as safety and tolerability.
Atossa’s Proprietary Endoxifen
Endoxifen is an active metabolite of tamoxifen. Tamoxifen is an
FDA-approved drug to prevent new breast cancer as well as recurrent
breast cancer in breast cancer patients. Tamoxifen itself must be
broken down by the liver into active compounds (metabolites), of
which Endoxifen is the most active. Atossa has completed a
comprehensive Phase 1 clinical study using both a topical and an
oral formulation of Endoxifen. Preliminary results from the topical
arm of the study indicated that the topical formulation was safe,
well tolerated and that topical Endoxifen crossed the skin barrier
in a dose-dependent fashion.
Topical Endoxifen Opportunity: MBD. Atossa is
developing its proprietary topical Endoxifen to reduce MBD, which
has been shown in studies conducted by others to be an independent
risk factor for developing breast cancer. To date, 30 U.S. states
require that findings of MBD be directly communicated to the
patient. Although oral tamoxifen has been shown to reduce MBD, the
benefit-risk ratio is generally not acceptable to most physicians
and their patients. For example, it is estimated that only ~ 2% of
women at high-risk of developing breast cancer, including those
with MBD, take oral tamoxifen to prevent breast cancer because of
the risk of, or actual side-effects of, oral tamoxifen.
Oral Endoxifen Opportunity. Approximately one
million breast cancer survivors take oral tamoxifen annually;
however, up to half of them do not properly metabolize tamoxifen
and do not have desired levels of Endoxifen (meaning they are
“refractory”). Low Endoxifen levels in breast cancer patients
taking oral tamoxifen are associated with an increased risk of
recurrence or the development of new breast tumors. Providing oral
Endoxifen directly to the patient without having to be metabolized
by the liver may help to address this problem.
Based on the number of women at high-risk of developing breast
cancer and the number of patients who have survived breast cancer
but are refractory to tamoxifen, Atossa estimates that the
potential markets for its proprietary oral and topical formulations
of Endoxifen could each potentially exceed $1 billion in annual
sales.
Breast Cancer Statistics
The American Cancer Society (ACS) estimates that approximately
250,000 women will be diagnosed with breast cancer in the United
States this year and that approximately 40,000 will die from the
disease. It is the second leading cause of cancer death in American
women. Although about 100 times less common than women, breast
cancer also affects men. The ACS estimates that the lifetime risk
of men getting breast cancer is about 1 in 1,000; 2,470 new cases
of invasive breast cancer will be diagnosed; and 460 men will die
from breast cancer in 2017.
About Stockholm South General Hospital
Stockholm South General Hospital is one of the largest hospitals
in Sweden, offering care to more than two million Stockholmers. It
is one of four hospitals collaborating with Karolinska on the KARMA
project. For more information, please visit
http://www.sodersjukhuset.se/Functions/InEnglish/.
About Karolinska Institutet
Karolinska Institutet, located in Stockholm, Sweden, is one of
the world’s foremost medical universities. Its vision is to make a
significant contribution to the improvement of human health; its
mission is to conduct research and education and to interact with
the community. As a university, KI is Sweden’s single largest
center of medical academic research and offers the country’s widest
range of medical courses and programs. The Nobel Assembly at
Karolinska Institutet selects the Nobel laureates in Physiology or
Medicine. For more information, please visit www.ki.se/en and
www.KARMAstudy.org.
About Atossa Genetics
Atossa Genetics Inc., is a clinical-stage pharmaceutical company
developing novel therapeutics and delivery methods to treat breast
cancer and other breast conditions. For more information, please
visit www.atossagenetics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with any variation between
preliminary and final clinical results, actions and inactions by
the FDA and other regulatory authorities, the outcome or timing of
regulatory approvals needed by Atossa, lower than anticipated rate
of patient enrollment, estimated market size of drugs under
development, the safety and efficacy of Atossa's products and
services, performance of clinical research organizations and
investigators, obstacles resulting from proprietary rights held by
others with respect to fulvestrant, such as patent rights,
potential market sizes for Atossa’s drugs under development and
other risks detailed from time to time in Atossa's filings with the
Securities and Exchange Commission, including without limitation
its periodic reports on Form 10-K and 10-Q, each as amended and
supplemented from time to time.
Atossa Genetics Company Contact:
Atossa Genetics Inc.Kyle GuseCFO and General Counsel(O) 866
893-4927kyle.guse@atossagenetics.com
Investor Relations Contact:
Scott GordonCoreIR377 Oak StreetConcourse 2Garden City, NY
11530Office: 516 222-2560scottg@CoreIR.com
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2023 to Apr 2024